

WEDNESDAY 17th JUNE 2015 COMMENCING 9.30 AM

AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN

AGENDA

- | | Enclosure |
|---|----------------------------|
| 1. Welcome and introduction | |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/0615 |
| 5. Chairman's report (verbal update) | |
| 6. Appraisal 1: Full Submission
Levonorgestrel (Jaydess [®]) for contraception for up to 3 years | 2/AWMSG/0615
Appendices |
| 7. Appraisal 2: Full Submission
Peginterferon beta-1a (Plegridy [®]) in adult patients for the treatment of relapsing remitting multiple sclerosis | 3/AWMSG/0615
Appendices |
| 8. Appraisal 3: Full Submission
Avanafil (Spedra [®]) for the treatment of erectile dysfunction in adult men | 4/AWMSG/0615
Appendices |
| 9. Appraisal 4: Limited Submission
Darunavir (Prezista [®]) co-administered with low dose ritonavir in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in paediatric patients from the age of 3 years and at least 15 kg body weight | 5/AWMSG/0615
Appendices |
| 10. National Audit: Focus on Antibiotic Prescribing – Update
For information | 6/AWMSG/0615 |
| 11. National Audit: Towards Appropriate Non-steroidal Anti-inflammatory Drug (NSAID) Prescribing – Update
For information | 7/AWMSG/0615 |

To protect commercial confidentiality, final appraisal will be conducted in private

12. **Appraisal 5: Full Submission (WPAS)**
Regorafenib (Stivarga®) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib

8/AWMSG/0615
Appendices

The meeting will open to the public for the announcement of the recommendation

Date of next meeting: 15th July 2015 in Cardiff